Home › Pharmacology › Class IV Antiarrhythmic Drugs

Class IV Antiarrhythmic Drugs

Q: Which drug groups should verapamil categorically not be combined with due to the risk of cardiac arrest?

Co-administration of verapamil with beta-blockers is highly undesirable. Drug interactions also include combinations with agents possessing negative inotropic effects, including sodium channel blockers, as well as other rate-lowering drugs.

Q: Why are Class IV antiarrhythmic drugs ineffective in ventricular arrhythmias?

Class IV antiarrhythmic drugs are ineffective in ventricular arrhythmias because their therapeutic action is localized primarily in the nodes of the cardiac conduction system. The physiological basis of their effect is the blockade of slow calcium channels. Pacemakers in the sinus and AV nodes generate "calcium" action potentials. Blockade of these channels reduces automaticity, and conduction, and increases the effective refractory period in the nodes, making these drugs effective only in supraventricular arrhythmias. In working ventricular cardiomyocytes, calcium channel blockade does not exert an antiarrhythmic effect, but rather causes an adverse effect — decreased myocardial contractility (negative inotropic effect).

Q: In which arrhythmias are Class IV drugs effective?

They are effective exclusively in supraventricular arrhythmias. They are ineffective against ventricular rhythm disorders.

Q: Why does diltiazem have low bioavailability despite good absorption?

Although diltiazem is absorbed by 90%, its bioavailability is only about 40% due to a prominent first-pass hepatic effect.

Q: How do calcium channel blockers affect blood pressure?

They act on angiomyocytes, causing blood vessel dilation (vasodilation), which naturally leads to arterial hypotension.

Q: What is the main cardiac adverse effect of verapamil?

Verapamil causes a negative inotropic effect (decreased contractility) and inhibits AV conduction, creating a risk for complete AV block and reduced cardiac pump function.

For medical students2 min readUpdated 2026-10-10

Class IV antiarrhythmic drugs are calcium channel blockers that decrease automaticity and conduction in the cardiac nodes. The primary agent in this group is verapamil, which is effective exclusively in the treatment of supraventricular arrhythmias.

Spectrum of actionSupraventricular arrhythmias only.

Main targetL-type calcium channels in the heart and blood vessels.

Drug of choiceVerapamil (belongs to the phenylalkylamine group).

Main riskReduced cardiac pump function and development of AV block.

Mechanism of Antiarrhythmic Action

The foundation of our heart rhythm relies on cardiac pacemakers. They generate so-called "calcium" action potentials. Calcium channel blockers (CCBs) interfere with this physiological process by decreasing automaticity and inhibiting conduction. This effect is predominantly realized in the nodes of the cardiac conduction system.

Due to this mechanism, Class IV drugs act as effective antiarrhythmics, but their spectrum of action is strictly limited: they are effective only in supraventricular arrhythmias.

Classification of Calcium Channel Blockers

The CCB group is extremely heterogeneous. Channel sensitivity to drugs directly depends on the chemical structure of the molecule. L-type channels dominate in the heart and blood vessels, though other types exist (e.g., T-type). There are 6 classes of CCBs based on their selectivity and site of action:

Class I selective CCBs (phenylalkylamines): The main representative is verapamil. The target is primarily L-channels of cardiomyocytes (heart).
Class II selective CCBs (dihydropyridines): These include nifedipine, amlodipine, and lacidipine. Their target is L-channels of vascular smooth muscle cells, exerting a pronounced effect on blood pressure.
Class III selective CCBs (benzothiazepines): Representative is diltiazem. It provides balanced blockade of L-channels in both the heart and blood vessels.
Class IV CCBs: Representative is cinnarizine. It is characterized by a predominant effect on cerebral blood vessels.
Class V CCBs: Representative is prenylamine (also belongs to phenylalkylamines).
Class VI CCBs: Representative is mibefradil. Its unique feature is the blockade of T-type calcium channels.

Pharmacology of Verapamil

Verapamil (Verapamil) is the main drug of choice for treating arrhythmias within this group. Chemically, it belongs to the phenylalkylamines.

Pharmacokinetics: Orally administered verapamil shows a high degree of absorption (90–92%) and binds extensively to plasma proteins (up to 90%). The peak effect develops in 1.5–2 hours, with a half-life of 3 to 7 hours. Elimination occurs via the kidneys and bile (unchanged and as conjugates).
Specific adverse effects: Caused by Ca²⁺ channel blockade. Cardiac effects include bradycardia (slowed heart rate) and decreased myocardial contractility. Conduction effects include suppression of atrioventricular (AV) conduction with a risk of complete AV block. Vascular effects may include arterial hypotension.
Nonspecific effects: Include allergic reactions and gastrointestinal disturbances (constipation, nausea, vomiting).

Characteristics of Diltiazem

Diltiazem (Diltiazem) is used less frequently as an antiarrhythmic agent. It belongs to the benzothiazepine group.

Pharmacokinetics: The drug is well absorbed (up to 90%), but its bioavailability remains low (about 40%) due to a pronounced first-pass effect. Action begins 30 minutes after administration, peak plasma concentration is reached in 3 hours, and the half-life is 3–4 hours. It is metabolized via acetylation and excreted through the intestine (unchanged and as metabolites).
Adverse effects: Mainly caused by vasodilation. Patients may experience headache and dizziness from the central nervous system. Cardiovascular effects may include reflex tachycardia and peripheral edema. Musculoskeletal effects such as muscle weakness are also noted.

Effects on Myocardium and Blood Vessels

In addition to antiarrhythmic action, CCBs exert systemic hemodynamic effects, which are often considered adverse effects when treating rhythm disorders.

Effect on myocardial contractility: Blockade of calcium channels in working ventricular cardiomyocytes leads to a decrease in the force of cardiac contractions (negative inotropic effect). The clinical significance of this phenomenon is high due to the risk of reducing cardiac pump function.
Effect on blood vessels: The drugs affect angiomyocytes (vascular smooth muscle cells), causing them to relax (vasodilation). A logical consequence of this process is the development of arterial hypotension.

Mnemonic

How to remember the selectivity of the first three classes: Verapamil — Heart (Class I), Diltiazem — Splits evenly (Class III, heart and vessels), Dihydropyridines — Pressure (Class II, vessels only).

Frequently asked questions

What are the absolute contraindications to the use of verapamil?

Contraindications and limitations for the use of verapamil include:

high-degree sinoatrial or atrioventricular block;
sick sinus syndrome and bradycardia (HR <60 bpm);
chronic heart failure and severe left ventricular dysfunction (LVEF <40%);
age under 1 year;
combination of atrial fibrillation with Wolff-Parkinson-White syndrome;
concurrent use of P-glycoprotein or CYP3A4-dependent drugs.

Which drug groups should verapamil categorically not be combined with due to the risk of cardiac arrest?

Co-administration of verapamil with beta-blockers is highly undesirable. Drug interactions also include combinations with agents possessing negative inotropic effects, including sodium channel blockers, as well as other rate-lowering drugs.

Why are Class IV antiarrhythmic drugs ineffective in ventricular arrhythmias?

Class IV antiarrhythmic drugs are ineffective in ventricular arrhythmias because their therapeutic action is localized primarily in the nodes of the cardiac conduction system. The physiological basis of their effect is the blockade of slow calcium channels. Pacemakers in the sinus and AV nodes generate "calcium" action potentials. Blockade of these channels reduces automaticity, and conduction, and increases the effective refractory period in the nodes, making these drugs effective only in supraventricular arrhythmias. In working ventricular cardiomyocytes, calcium channel blockade does not exert an antiarrhythmic effect, but rather causes an adverse effect — decreased myocardial contractility (negative inotropic effect).

In which arrhythmias are Class IV drugs effective?